Cancer

TORONTO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd.  (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that Revive has entered into an exclusive license agreement with Puerto Rico Science Technology and Research Trust , representing Universidad Central del Caribe  and St. Jude Children’s Research Hospital, for the intellectual property (International Patent Application No.

National Institute of Cancer prevention and research (NICPR) was initially established as Cytology Research Centre (CRC) by the Indian Council of Medical Research (ICMR) in 1979, and was elevated to the level of an Institute in 1989. It was granted national status in 2016 acknowledging its mandate and contributions towards cancer prevention. The institute has broadened its horizon to cater to prevention of prevalent cancers in the country.

The National Institute of Immunology (NII) is committed to advanced research addressing the basic mechanisms involved in body's defence to identify modalities for manipulation of the immune system to provide protection against diseases and understand mechanisms that can be used to target disease processes for intervention. The institute’s research thrust areas under immunology and related disciplines cluster in four main themes, namely, infection and immunity, molecular design, gene regulation and reproduction and development, where cutting edge research in modern biology is being carried out.

Post : Junior Research Fellow/Senior Research Fellow & Data Entry Operator (Project)

The mission of ETR is to coordinate the various IARC training initiatives and promote them both internally and externally. The Group is under the direction of an Education and Training Officer, with two Senior Programme Assistants managing the fellowship and courses programmes.

Post : POSTDOCTORAL FELLOWSHIPS

ABOUT AUTHOR
DR. PRANJAL BORDOLOI
VP – PHARMACOLGY & COD
VEEDA CLINICAL RESEARCH PVT LTD.
info@veedacr.com

Therapeutic innovation in cancer treatment has always been in focus. Based on WHO data, worldwide, there were 14.1 million new cancer cases, 8.2 million cancer deaths, and 32.6 million people living with cancer within 5 years of diagnosis by year 2012. Top 5 most frequent cancers in world (ranked by number of new cases) are breast, prostate, lung, colorectal, and cervical cancers per 2012 WHO data (International Agency for Research on Cancer, WHO). For countries like India, the top 5 most frequent cancers (ranked by number of new cases) are breast, cervical, oral cavity, lung and colorectal cancers (International Agency for Research on Cancer, WHO). Reported age-adjusted incidence rates for cancer are still quite low in the demographically young country. Little more than 1 million new cases of cancer are diagnosed every year in India. An estimated 600 000–700 000 deaths in India were caused by cancer in 2012. In age-standardized terms this is close to the mortality burden seen in high-income countries. Such figures are somewhat indicative of low rates of early-stage detection and poor treatment outcomes (Mallath MK, et al. 2014).